source
- FDA places uniQure’s Huntington’s gene therapy in priority review, targeting May 2027 approvalThe U.S. Food and Drug Administration has accepted uniQure’s filing for its Huntington’s disease gene therapy and placed the product under priority review, a step that could accelerate a decision b…
- Four major drugmakers allegedly paid tens of millions to Russian middlemen for lifesaving drugs, limiting patient accessFour large pharmaceutical companies are accused of funneling tens of millions of dollars to Russian intermediaries to deliver essential medicines to government agencies, according to a report by th…STAT · 6d agoRegulatoryNegative